Generation Bio Co.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Charles A Jr Rowland. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Charles A Jr Rowland has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ORTX / Orchard Therapeutics plc - Depositary Receipt (Common Stock) Director 0
US:GBIO / Generation Bio Co. Director 534,757
US:VKTX / Viking Therapeutics, Inc. Director 30,000
US:NBRV / Nabriva Therapeutics Plc Director 15,277
US:BPMC / Blueprint Medicines Corporation Director 4,500
Director 10,100
US:VTAE / Vitae Pharmaceuticals, Inc. Director 0
US:BIND / BIND Therapeutics, Inc. Director 0
US:IDIX / Idenix Pharmaceuticals Inc Director 0
US:VPHM / Shire Viropharma Inc VP, Chief Financial Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Charles A Jr Rowland. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases GBIO / Generation Bio Co. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GBIO / Generation Bio Co.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-12-04 GBIO Rowland Charles A Jr 150,000 1.5000 15,000 15.0000 225,000 126 4.3500 -159,750 -71.00
2023-12-01 GBIO Rowland Charles A Jr 192,960 1.3100 19,296 13.1000 252,778
2022-09-19 GBIO Rowland Charles A Jr 15,750 5.2600 1,575 52.6000 82,845
2022-09-16 GBIO Rowland Charles A Jr 33,481 5.4800 3,348 54.8000 183,476
2022-09-15 GBIO Rowland Charles A Jr 17,147 5.4100 1,715 54.1000 92,765
2022-09-14 GBIO Rowland Charles A Jr 5,600 5.2950 560 52.9500 29,652
2022-09-13 GBIO Rowland Charles A Jr 18,784 5.2040 1,878 52.0400 97,752
2021-01-11 GBIO Rowland Charles A Jr 20,408 24.5000 2,041 245.0000 499,996
2020-06-16 GBIO Rowland Charles A Jr 30,000 19.0000 3,000 190.0000 570,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GBIO / Generation Bio Co. Insider Trades
Insider Sales GBIO / Generation Bio Co. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GBIO / Generation Bio Co.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GBIO / Generation Bio Co. Insider Trades
Insider Purchases NBRVF / Nabriva Therapeutics plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GBIO / Generation Bio Co.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-12-24 NBRV Rowland Charles A Jr 53,000 1.3100 3,029 22.9250 69,430 86 792.5 2,330,260 3,356.27

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NBRVF / Nabriva Therapeutics plc Insider Trades
Insider Sales NBRVF / Nabriva Therapeutics plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GBIO / Generation Bio Co.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2022-08-01 NBRV Rowland Charles A Jr 8,496 0.1750 340 4.3750 1,487 158 1.3000 -1,045 -70.34
2021-08-02 NBRV Rowland Charles A Jr 777 1.2000 31 30.0000 932

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NBRVF / Nabriva Therapeutics plc Insider Trades
Insider Purchases VKTX / Viking Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GBIO / Generation Bio Co.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-05-29 VKTX Rowland Charles A Jr 30,000 5.1600 30,000 5.1600 154,800 113 19.65 434,700 280.81

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VKTX / Viking Therapeutics, Inc. Insider Trades
Insider Sales VKTX / Viking Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GBIO / Generation Bio Co.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VKTX / Viking Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Charles A Jr Rowland as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-01-24 2024-01-24 4 ORTX Orchard Therapeutics plc
Ordinary Shares
D - Sale to Issuer -12,294 0 -100.00
2023-12-05 2023-12-04 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 150,000 534,757 38.99 1.50 225,000 802,136
2023-12-05 2023-12-01 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 192,960 384,757 100.61 1.31 252,778 504,032
2023-05-18 2023-05-16 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -40,000 30,000 -57.14 25.00 -1,000,000 750,000
2023-05-18 2023-05-16 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
M - Exercise X 40,000 70,000 133.33 1.08 43,200 75,600
2022-09-20 2022-09-19 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 15,750 191,797 8.95 5.26 82,845 1,008,852
2022-09-19 2022-09-16 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 33,481 176,047 23.48 5.48 183,476 964,738
2022-09-19 2022-09-15 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 17,147 142,566 13.67 5.41 92,765 771,282
2022-09-15 2022-09-14 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 5,600 125,419 4.67 5.30 29,652 664,094
2022-09-15 2022-09-13 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 18,784 119,819 18.59 5.20 97,752 623,538
2022-08-03 2022-08-01 4 NBRV Nabriva Therapeutics plc
Ordinary Shares
S - Sale -8,496 15,277 -35.74 0.18 -1,487 2,673
2022-01-05 2022-01-03 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2021-08-04 2021-08-02 4 NBRV Nabriva Therapeutics plc
Ordinary Shares
S - Sale -777 23,773 -3.16 1.20 -932 28,528
2021-07-30 2021-07-28 4 NBRV Nabriva Therapeutics plc
Share Options
A - Award 35,000 35,000
2021-07-30 2021-07-28 4 NBRV Nabriva Therapeutics plc
Ordinary Shares
A - Award 17,500 24,550 248.23
2021-06-17 2021-06-16 4 ORTX Orchard Therapeutics plc
Stock Option (Right to Buy)
A - Award 40,000 40,000
2021-06-11 2021-06-09 4 GBIO Generation Bio Co.
Stock Option (right to buy)
A - Award 15,000 15,000
2021-06-04 2021-06-02 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 4,500 4,500
2021-06-04 2021-06-02 4 BPMC Blueprint Medicines Corp
Common Stock
A - Award 2,250 5,812 63.17
2021-01-13 2021-01-11 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 20,408 101,035 25.31 24.50 499,996 2,475,358
2021-01-06 2021-01-04 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2020-12-18 2020-12-17 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
M - Exercise -10,909 0 -100.00
2020-12-18 2020-12-17 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -10,909 3,562 -75.39 117.82 -1,285,298 419,675
2020-12-18 2020-12-17 4 BPMC Blueprint Medicines Corp
Common Stock
M - Exercise 10,909 14,471 306.26 19.53 213,053 282,619
2020-11-04 2020-11-03 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
M - Exercise -5,522 0 -100.00
2020-11-04 2020-11-03 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -694 3,562 -16.31 95.97 -66,603 341,845
2020-11-04 2020-11-03 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -4,728 4,256 -52.63 99.10 -468,545 421,770
2020-11-04 2020-11-03 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -100 8,984 -1.10 100.48 -10,048 902,712
2020-11-04 2020-11-03 4 BPMC Blueprint Medicines Corp
Common Stock
M - Exercise 5,522 9,084 155.03 9.46 52,238 85,935
2020-11-04 2020-11-02 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
M - Exercise -4,478 5,522 -44.78
2020-11-04 2020-11-02 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -4,478 3,562 -55.70 99.11 -443,815 353,030
2020-11-04 2020-11-02 4 BPMC Blueprint Medicines Corp
Common Stock
M - Exercise 4,478 8,040 125.72 9.46 42,362 76,058
2020-07-31 2020-07-29 4 NBRV Nabriva Therapeutics plc
Stock Options
A - Award 35,000 35,000
2020-07-31 2020-07-29 4 NBRV Nabriva Therapeutics plc
Ordinary Shares
A - Award 17,500 70,500 33.02
2020-06-26 2020-06-24 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 4,500 4,500
2020-06-26 2020-06-24 4 BPMC Blueprint Medicines Corp
Common Stock
A - Award 2,250 3,562 171.49
2020-06-23 2020-06-19 4 BPMC Blueprint Medicines Corp
Restricted Stock Units
M - Exercise -1,312 0 -100.00
2020-06-23 2020-06-19 4 BPMC Blueprint Medicines Corp
Common Stock
M - Exercise 1,312 1,312
2020-06-19 2020-06-17 4 ORTX Orchard Therapeutics plc
Stock Option (Right to Buy)
A - Award 35,000 35,000
2020-06-18 2020-06-16 4 GBIO Generation Bio Co.
Series C Preferred Stock
C - Conversion -89,423 0 -100.00
2020-06-18 2020-06-16 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 30,000 80,627 59.26 19.00 570,000 1,531,913
2020-06-18 2020-06-16 4 GBIO Generation Bio Co.
Common Stock
C - Conversion 50,627 50,627
2020-06-15 2020-06-11 4 GBIO Generation Bio Co.
Stock Option (right to buy)
A - Award 52,000 52,000
2020-01-03 2020-01-02 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2020-01-02 3 ORTX Orchard Therapeutics plc
Ordinary Shares
24,588
2020-01-02 3 ORTX Orchard Therapeutics plc
Ordinary Shares
24,588
2020-01-02 3 ORTX Orchard Therapeutics plc
Ordinary Shares
24,588
2019-08-01 2019-07-31 4 NBRV Nabriva Therapeutics plc
Stock Option
A - Award 35,000 35,000
2019-06-24 2019-06-20 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
M - Exercise -11,818 10,000 -54.17
2019-06-24 2019-06-20 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -9,271 0 -100.00 94.83 -879,169
2019-06-24 2019-06-20 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -1,600 9,271 -14.72 96.08 -153,728 890,758
2019-06-24 2019-06-20 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -947 10,871 -8.01 96.69 -91,565 1,051,117
2019-06-24 2019-06-20 4 BPMC Blueprint Medicines Corp
Common Stock
M - Exercise 11,818 11,818 9.46 111,798 111,798
2019-06-20 2019-06-19 4 BPMC Blueprint Medicines Corp
Restricted Stock Units
A - Award 1,312 1,312
2019-06-20 2019-06-19 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 4,875 4,875
2019-01-03 2019-01-02 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2018-12-27 2018-12-24 4 NBRV Nabriva Therapeutics plc
Ordinary Shares
P - Purchase 53,000 53,000 1.31 69,430 69,430
2018-08-02 2018-08-01 4 NBRV Nabriva Therapeutics plc
Stock Option
A - Award 10,000 10,000
2018-06-25 2018-06-21 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 7,500 51,136 17.19
2018-05-31 2018-05-29 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
P - Purchase 30,000 30,000 5.16 154,800 154,800
2018-05-04 2018-05-02 4 NBRV Nabriva Therapeutics plc
Stock Option
A - Award 29,000 29,000
2018-01-03 2018-01-02 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16,000 16,000
2017-09-19 2017-09-15 4 NBRV Nabriva Therapeutics plc
Stock Option
A - Award 10,100 10,100
2017-07-05 2017-07-01 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 40,000 40,000
2017-06-27 2017-06-23 4 NBRV Nabriva Therapeutics Plc
Stock Option
J - Other 10,100 10,100
2017-06-27 2017-06-23 4 NBRV Nabriva Therapeutics Plc
Stock Option
J - Other 16,000 16,000
2017-06-23 2017-06-21 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 10,909 43,636 33.33
2016-10-25 2016-10-25 4 VTAE Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
D - Sale to Issuer -10,000 0 -100.00 11.38 -113,800
2016-10-25 2016-10-25 4 VTAE Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
D - Sale to Issuer -10,000 0 -100.00 8.57 -85,700
2016-10-25 2016-10-25 4 VTAE Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
D - Sale to Issuer -17,000 0 -100.00 13.00 -221,000
2016-08-30 2016-08-26 4 BIND DNIB UNWIND, INC.
Employee Stock Option (Right to Buy)
M - Exercise -15,000 0 -100.00
2016-08-30 2016-08-26 4 BIND DNIB UNWIND, INC.
Common Stock
M - Exercise 15,000 15,000 0.44 6,600 6,600
2016-06-27 2016-06-23 4 BPMC Blueprint Medicines Corp
Stock Option (Right to Buy)
A - Award 10,909 32,727 50.00
2016-06-22 2016-06-21 4 BIND BIND Therapeutics, Inc
Employee Stock Option (Right to Buy)
A - Award 15,000 15,000
2016-05-27 2016-05-26 4 VTAE Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
A - Award 10,000 10,000
2015-06-10 2015-06-09 4 BIND BIND Therapeutics, Inc
Employee Stock Option (Right to Buy)
A - Award 15,000 15,000
2015-06-01 2015-05-28 4 VTAE Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
A - Award 10,000 10,000
2014-09-26 2014-09-24 4 VTAE Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
A - Award 17,000 17,000
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-08-05 2014-08-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00
2014-06-06 2014-06-05 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2014-05-29 2014-05-28 4 BIND BIND Therapeutics, Inc
Employee Stock Option (Right to Buy)
A - Award 25,000 25,000
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -15,756 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -32,516 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -34,570 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -35,723 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -27,265 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -40,261 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -40,261 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -50,000 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -13,714 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
D - Sale to Issuer -52,593 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Common Stock
D - Sale to Issuer -48,878 0 -100.00
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Common Stock
A - Award 48,878 48,878
2014-01-28 2014-01-24 4 VPHM VIROPHARMA INC
Common Stock
U - Other -87,026 0 -100.00 50.00 -4,351,300
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -1,852 52,593 -3.40
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -8,361 15,756 -34.67
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -13,080 13,714 -48.82
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -5,460 0 -100.00
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -558 87,026 -0.64 49.80 -27,788 4,333,895
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 1,852 87,584 2.16 13.50 25,002 1,182,384
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -2,271 85,732 -2.58 49.80 -113,096 4,269,454
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 8,361 88,003 10.50 11.96 99,998 1,052,516
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -2,773 79,642 -3.36 49.80 -138,095 3,966,172
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 13,080 82,415 18.86 8.86 115,889 730,197
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -847 69,335 -1.21 49.80 -42,181 3,452,883
2014-01-10 2014-01-08 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 5,460 70,182 8.44 5.91 32,269 414,776
2013-12-31 2013-12-27 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -4,540 5,460 -45.40
2013-12-31 2013-12-27 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -704 64,722 -1.08 49.86 -35,101 3,227,039
2013-12-31 2013-12-27 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 4,540 65,426 7.46 5.91 26,831 386,668
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -23,206 26,794 -46.41
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -10,000 10,000 -50.00
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -15,800 24,117 -39.58
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -11,835 60,886 -16.27 49.74 -588,673 3,028,470
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 23,206 72,721 46.87 8.86 205,605 644,308
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -3,964 49,515 -7.41 49.74 -197,169 2,462,876
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 10,000 53,479 23.00 5.91 59,100 316,061
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -9,330 43,479 -17.67 49.74 -464,074 2,162,645
2013-12-20 2013-12-18 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 15,800 52,809 42.69 11.96 188,968 631,596
2013-06-12 2013-06-10 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
A - Award 32,516 32,516
2013-06-10 2013-06-06 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2013-06-10 2013-06-06 4 IDIX IDENIX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2013-01-07 2013-01-03 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
A - Award 34,570 34,570
2012-06-06 2012-06-04 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
A - Award 35,723 35,723
2012-03-09 2012-03-07 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -5,555 54,445 -9.26
2012-03-09 2012-03-07 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -25,083 39,917 -38.59
2012-03-09 2012-03-07 4 VPHM VIROPHARMA INC
Common Stock
F - Taxes -12,715 35,048 -26.62 29.49 -374,965 1,033,566
2012-03-09 2012-03-07 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 5,555 47,763 13.16 13.50 74,992 644,800
2012-03-09 2012-03-07 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 25,083 42,208 146.47 11.96 299,993 504,808
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -25,000 50,000 -33.33
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -10,000 20,000 -33.33
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
M - Exercise -35,000 65,000 -35.00
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Common Stock
S - Sale -12,750 17,125 -42.68 32.11 -409,434 549,927
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Common Stock
S - Sale -70,000 29,875 -70.09 32.12 -2,248,197 959,498
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 25,000 99,875 33.39 8.86 221,500 884,892
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 10,000 74,875 15.41 5.91 59,100 442,511
2012-03-05 2012-03-01 4 VPHM VIROPHARMA INC
Common Stock
M - Exercise 35,000 64,875 117.15 11.96 418,600 775,905
2012-01-06 2012-01-05 4 VPHM VIROPHARMA INC
Employee Stock Option (Right to Buy)
A - Award 27,265 27,265
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)